Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AS1404

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
BACKGROUND DMXAA (5,6-dimethylxanthenone-4-acetic acid; AS1404), a vascular disrupting agent currently in clinical trials… Expand
Is this relevant?
2007
2007
4642 The anti-VEGF monoclonal antibody, bevacizumab, has been approved for use alongside chemotherapy in colorectal, non-small… Expand
Is this relevant?
2007
2007
Purpose5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (AS1404), a small-molecule vascular disrupting agent currently in clinical… Expand
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2007
2007
Pharma's pipeline problems, coupled with the trend toward acquisition, are giving biotechs more leverage in licensing discussions… Expand
Is this relevant?
2006
2006
Purpose 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) (AS1404) is a novel antitumour agent that selectively disrupts tumour… Expand
  • table 1
  • figure 1
  • figure 4
  • figure 2
  • figure 5
Is this relevant?
2006
2006
SummaryAims: DMXAA (AS1404), a small-molecule vascular disrupting agent that has now completed Phase II clinical trial, induces… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2006
2006
  • Mark James McKeage
  • Journal of clinical oncology : official journal…
  • 2006
  • Corpus ID: 22849845
7102 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra… Expand
Is this relevant?
2006
2006
  • Hani Gabra
  • Journal of clinical oncology : official journal…
  • 2006
  • Corpus ID: 23536090
5032 Background: DMXAA (AS1404) is a small-molecule vascular disrupting agent, which in animal models shows additive or supra… Expand
Is this relevant?
2005
2005
The selective targeting of established tumor vasculature represents an attractive new anticancer drug strategy, distinct from… Expand
  • figure 2
  • table 1
Is this relevant?